Niagen Bioscience (NAGE) Revenue (2010 - 2026)

Niagen Bioscience (NAGE) has 17 years of Revenue data on file, last reported at $31.5 million in Q1 2026.

• On a quarterly basis, Revenue rose 3.26% year-over-year to $31.5 million in Q1 2026; TTM through Mar 2026 was $130.4 million, a 20.84% increase from a year earlier, with the FY2025 full-year figure at $129.4 million, up 29.95% from the prior year.
• Revenue for Q1 2026 stood at $31.5 million, down from $33.8 million in the prior quarter.
• Over the last five years, Revenue for NAGE reached as high as $34.0 million in Q3 2025 and fell as low as $16.7 million in Q2 2022.
• Historically, Revenue has averaged $24.5 million across 5 years, with a median of $22.6 million in 2023.
• Across the five-year window, Revenue retreated 5.46% in 2022 and jumped 37.59% in 2025, its largest moves.
• Year by year, Revenue stood at $21.0 million in 2022, then increased by 0.95% to $21.2 million in 2023, then jumped by 37.41% to $29.1 million in 2024, then grew by 16.19% to $33.8 million in 2025, then dropped by 6.99% to $31.5 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $31.5 million in Q1 2026, $33.8 million in Q4 2025, and $34.0 million in Q3 2025.